中基健康(000972) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥42,964,683.12, an increase of 5,271.56% compared to the same period last year[9]. - Net profit attributable to shareholders of the listed company was ¥2,667,106.83, with a year-to-date loss of ¥42,077,086.68[9]. - Basic earnings per share for the reporting period were ¥0.003, compared to a loss of ¥0.0546 in the same period last year[9]. - The weighted average return on net assets was 0.61%, an increase of 1.76 percentage points year-on-year[9]. - The company reported a net loss attributable to shareholders of ¥42,077,086.68, a decrease of 284.06% from a profit of ¥22,860,511.96 in the previous period[16]. - The total comprehensive income decreased by 285.52% to a loss of ¥42,112,313.51 from a profit of ¥22,699,015.33 in the previous period[16]. - The company reported a net loss of CNY 42,112,313.51 for Q3 2020, compared to a net profit of CNY 22,699,015.33 in the same period last year, indicating a significant decline in profitability[49]. Assets and Liabilities - Total assets at the end of the reporting period were ¥669,410,187.63, a decrease of 9.57% compared to the end of the previous year[9]. - Net assets attributable to shareholders of the listed company were ¥399,819,294.00, down 9.53% year-on-year[9]. - Total liabilities decreased from CNY 292,346,652.15 to CNY 263,554,151.72, a decline of about 9.8%[33]. - The company’s non-current assets decreased from CNY 403,980,721.84 to CNY 370,929,921.21, a reduction of approximately 8.2%[32]. - The company’s accounts payable increased by 131.15% to ¥64,724,799.20 from ¥28,000,855.36, indicating outstanding payments for outsourced services[16]. Cash Flow - The company reported a net cash flow from operating activities of -¥1,669,475.90 for the reporting period[9]. - Cash received from sales of goods and services dropped by 86.31% to ¥14,893,861.00 from ¥108,777,383.74, reflecting the impact of business transformation[17]. - The company generated CNY 64,895,309.33 in cash inflows from operating activities, down from CNY 135,028,231.07 in the previous year[54]. - The net cash flow from operating activities was -63,094,886.90 CNY, compared to -36,717,135.48 CNY in the previous period, indicating a significant increase in cash outflow[59]. - The company reported a total cash outflow of 86,593,897.30 CNY from operating activities, which is significantly higher than the previous period's outflow of 53,723,430.56 CNY[59]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,141[11]. - The top ten shareholders held a combined 42.70% of the company's shares, with the largest shareholder holding 16.18%[12]. Business Transformation and Strategy - The company plans to issue shares to raise funds for the modernization of traditional Chinese medicine and emergency medical supplies production, which will change its main business focus[18]. - The company is focusing on market expansion and new product development as part of its strategic initiatives[41]. Research and Development - Research and development expenses for Q3 2020 were CNY 10,179,080.15, indicating ongoing investment in innovation[41]. - Research and development expenses amounted to CNY 11,721,700.00, reflecting the company's commitment to innovation despite financial losses[49]. Audit and Verification - The report was not audited, indicating that the figures presented may be subject to further verification[60].